S&P 500   3,934.11 (-0.18%)
DOW   33,617.94 (+0.06%)
QQQ   280.41 (-0.45%)
AAPL   141.04 (-1.31%)
MSFT   244.28 (-0.34%)
META   113.54 (-0.51%)
GOOGL   95.22 (-1.81%)
AMZN   87.97 (-0.32%)
TSLA   173.54 (-3.49%)
NVDA   159.37 (-0.31%)
NIO   12.58 (-4.98%)
BABA   88.82 (-2.88%)
AMD   70.58 (+0.44%)
T   19.34 (+0.89%)
MU   53.48 (-0.37%)
CGC   3.30 (-8.59%)
F   13.28 (+0.00%)
GE   85.32 (+0.05%)
DIS   92.47 (+0.20%)
AMC   6.39 (-5.33%)
PYPL   73.77 (+2.13%)
PFE   50.42 (+1.43%)
NFLX   306.72 (+0.38%)
S&P 500   3,934.11 (-0.18%)
DOW   33,617.94 (+0.06%)
QQQ   280.41 (-0.45%)
AAPL   141.04 (-1.31%)
MSFT   244.28 (-0.34%)
META   113.54 (-0.51%)
GOOGL   95.22 (-1.81%)
AMZN   87.97 (-0.32%)
TSLA   173.54 (-3.49%)
NVDA   159.37 (-0.31%)
NIO   12.58 (-4.98%)
BABA   88.82 (-2.88%)
AMD   70.58 (+0.44%)
T   19.34 (+0.89%)
MU   53.48 (-0.37%)
CGC   3.30 (-8.59%)
F   13.28 (+0.00%)
GE   85.32 (+0.05%)
DIS   92.47 (+0.20%)
AMC   6.39 (-5.33%)
PYPL   73.77 (+2.13%)
PFE   50.42 (+1.43%)
NFLX   306.72 (+0.38%)
S&P 500   3,934.11 (-0.18%)
DOW   33,617.94 (+0.06%)
QQQ   280.41 (-0.45%)
AAPL   141.04 (-1.31%)
MSFT   244.28 (-0.34%)
META   113.54 (-0.51%)
GOOGL   95.22 (-1.81%)
AMZN   87.97 (-0.32%)
TSLA   173.54 (-3.49%)
NVDA   159.37 (-0.31%)
NIO   12.58 (-4.98%)
BABA   88.82 (-2.88%)
AMD   70.58 (+0.44%)
T   19.34 (+0.89%)
MU   53.48 (-0.37%)
CGC   3.30 (-8.59%)
F   13.28 (+0.00%)
GE   85.32 (+0.05%)
DIS   92.47 (+0.20%)
AMC   6.39 (-5.33%)
PYPL   73.77 (+2.13%)
PFE   50.42 (+1.43%)
NFLX   306.72 (+0.38%)
S&P 500   3,934.11 (-0.18%)
DOW   33,617.94 (+0.06%)
QQQ   280.41 (-0.45%)
AAPL   141.04 (-1.31%)
MSFT   244.28 (-0.34%)
META   113.54 (-0.51%)
GOOGL   95.22 (-1.81%)
AMZN   87.97 (-0.32%)
TSLA   173.54 (-3.49%)
NVDA   159.37 (-0.31%)
NIO   12.58 (-4.98%)
BABA   88.82 (-2.88%)
AMD   70.58 (+0.44%)
T   19.34 (+0.89%)
MU   53.48 (-0.37%)
CGC   3.30 (-8.59%)
F   13.28 (+0.00%)
GE   85.32 (+0.05%)
DIS   92.47 (+0.20%)
AMC   6.39 (-5.33%)
PYPL   73.77 (+2.13%)
PFE   50.42 (+1.43%)
NFLX   306.72 (+0.38%)
NASDAQ:LIVN

LivaNova - LIVN Stock Forecast, Price & News

$54.15
+0.14 (+0.26%)
(As of 12/7/2022 12:21 PM ET)
Add
Compare
Today's Range
$53.98
▼
$54.56
50-Day Range
$43.88
▼
$56.16
52-Week Range
$41.82
▼
$89.69
Volume
2,441 shs
Average Volume
440,483 shs
Market Capitalization
$2.90 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$83.00

LivaNova MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
52.9% Upside
$83.00 Price Target
Short Interest
Healthy
3.51% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.53mentions of LivaNova in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
42.20%
From $1.73 to $2.46 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.49 out of 5 stars

Medical Sector

166th out of 1,027 stocks

Electromedical Equipment Industry

5th out of 23 stocks

See Top Rated MarketRank™ Stocks Here
LIVN stock logo

About LivaNova (NASDAQ:LIVN) Stock

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.

Receive LIVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LivaNova and its competitors with MarketBeat's FREE daily newsletter.

LIVN Stock News Headlines

December 4, 2022 | americanbankingnews.com
Analysts Set LivaNova PLC (NASDAQ:LIVN) Target Price at $83.00
November 24, 2022 | finance.yahoo.com
Should You Think About Buying LivaNova PLC (NASDAQ:LIVN) Now?
November 7, 2022 | finance.yahoo.com
LivaNova (NASDAQ:LIVN) Is Experiencing Growth In Returns On Capital
November 2, 2022 | finance.yahoo.com
LivaNova Reports Third-Quarter 2022 Results
October 26, 2022 | finance.yahoo.com
LivaNova (LIVN) Expected to Beat Earnings Estimates: Should You Buy?
October 21, 2022 | finance.yahoo.com
Breakeven Is Near for LivaNova PLC (NASDAQ:LIVN)
October 19, 2022 | globenewswire.com
Ventricular Assist Devices Market Report (2022 to 2030) - Abiomed, Inc., Medtronic Plc, Abbott Laboratories, LivaNova PLC, Boston Scientific Corporation and Jarvik Heart, Inc - GlobeNewswire
October 13, 2022 | seekingalpha.com
LivaNova Loses Profit Momentum On Higher R&D Expense (NASDAQ:LIVN) - Seeking Alpha
October 6, 2022 | finance.yahoo.com
Global Heart Lung Machine Market Report to 2031 - Industry Analysis, Size, Share, Growth, Trends, and Forecasts - Yahoo Finance
October 6, 2022 | globenewswire.com
With 5.3% CAGR, Defibrillator Market Size worth USD - GlobeNewswire
October 5, 2022 | globenewswire.com
At 5.6% CAGR, Global Medical Perfusion Technology Market Size to Hit USD 905.50 Million by 2026: Facts & Factors - GlobeNewswire
September 30, 2022 | nasdaq.com
21%of this LivaNova PLC (NASDAQ:LIVN) insider's holdings were sold in the last year - Nasdaq
September 30, 2022 | benzinga.com
FDA Says Livanova Recalls Lifesparc System For Risk Of Unintentional Extended Pump Stop During Controller - Benzinga
September 30, 2022 | seekingalpha.com
FDA labels recall of blood bypass pump systems by LivaNova as most serious - Seeking Alpha
September 30, 2022 | nasdaq.com
LivaNova Enters Oversold Territory (LIVN)
September 27, 2022 | finance.yahoo.com
Neuromodulation Devices Global Market - Forecast To 2029 - Yahoo Finance
September 26, 2022 | benzinga.com
Worldwide Heart Lung Machine Industry to 2031 - Featuring Hemovent, LivaNova, Medtronic and Nipro Among O - Benzinga
September 16, 2022 | finance.yahoo.com
Outlook on the Endoscopic Vessel Harvesting System Global Market to 2027 - Growing Healthcare Market Presents Opportunities - Yahoo Finance
September 14, 2022 | bizjournals.com
2022 Fire Awards, Exits of the Year: ALung Technologies - The Business Journals
September 12, 2022 | finance.yahoo.com
Internal Neurostimulation Devices Market is Thriving at CAGR Of +17.4% by 2029, Size, Share, Emerging Trends, Historic Analysis, Competitive Landscape and Industry Growth Factors - Yahoo Finance
September 8, 2022 | bizjournals.com
Carlson Center's small neighbors sign new tenants, including Roers Cos. - The Business Journals
August 26, 2022 | nasdaq.com
Slowing Rates Of Return At LivaNova (NASDAQ:LIVN) Leave Little Room For Excitement - Nasdaq
August 24, 2022 | reuters.com
LIVN.O - LivaNova PLC | Stock Price & Latest News | Reuters
August 18, 2022 | nasdaq.com
Sum Up The Parts: IVOO Could Be Worth $200 - Nasdaq
August 12, 2022 | msn.com
LivaNova's Return on Invested Capital Overview
See More Headlines
Receive LIVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LivaNova and its competitors with MarketBeat's FREE daily newsletter.

LIVN Company Calendar

Last Earnings
11/02/2022
Today
12/07/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/22/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LIVN
CUSIP
N/A
CIK
1639691
Web
www.livanova.com
Phone
442033250660
Fax
281-218-9332
Employees
3,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$83.00
High Stock Price Forecast
$96.00
Low Stock Price Forecast
$63.00
Forecasted Upside/Downside
+53.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.75)
Trailing P/E Ratio
N/A
Forward P/E Ratio
31.30
P/E Growth
N/A
Net Income
$-135,820,000.00
Net Margins
-9.14%
Pretax Margin
-8.24%
Return on Equity
9.28%
Return on Assets
5.07%

Debt

Debt-to-Equity Ratio
0.45
Current Ratio
2.96
Quick Ratio
2.53

Sales & Book Value

Annual Sales
$1.04 billion
Price / Sales
2.80
Cash Flow
$3.53 per share
Price / Cash Flow
15.33
Book Value
$24.32 per share
Price / Book
2.23

Miscellaneous

Outstanding Shares
53,520,000
Free Float
53,320,000
Market Cap
$2.90 billion
Optionable
Optionable
Beta
0.87

Key Executives

  • Mr. Damien McDonaldMr. Damien McDonald (Age 57)
    CEO & Director
    Comp: $3.48M
  • Mr. Alex Shvartsburg (Age 51)
    Chief Financial Officer
    Comp: $888.04k
  • Ms. Trui Hebbelinck (Age 50)
    Chief HR Officer
    Comp: $945.32k
  • Ms. Keyna Pidcock Skeffington (Age 59)
    Sr. VP, Special Advisor & Exec. Officer
    Comp: $1.19M
  • Mr. Marco DolciMr. Marco Dolci (Age 60)
    Pres of Cardiopulmonary Bus. Unit
    Comp: $1.29M
  • Lindsey Little
    Sr. Director of Investor Relations
  • Mr. Michael Hutchinson
    Sr. VP, Chief Legal Officer and Company Sec.
  • Deanna Wilke
    VP of Corp. Communications
  • Mr. Matthew Joseph Dodds III
    Sr. VP of Corp. Devel.
  • Dr. Bryan D. Olin Ph.D. (Age 55)
    Sr. VP & Head of Product Devel. - Neuromodulation

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













LIVN Stock - Frequently Asked Questions

Should I buy or sell LivaNova stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for LivaNova in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LIVN shares.
View LIVN analyst ratings or view top-rated stocks.

What is LivaNova's stock price forecast for 2023?

4 analysts have issued 12-month target prices for LivaNova's shares. Their LIVN share price forecasts range from $63.00 to $96.00. On average, they expect the company's share price to reach $83.00 in the next twelve months. This suggests a possible upside of 52.4% from the stock's current price.
View analysts price targets for LIVN or view top-rated stocks among Wall Street analysts.

How have LIVN shares performed in 2022?

LivaNova's stock was trading at $87.43 at the beginning of the year. Since then, LIVN stock has decreased by 37.7% and is now trading at $54.45.
View the best growth stocks for 2022 here.

When is LivaNova's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our LIVN earnings forecast.

How were LivaNova's earnings last quarter?

LivaNova PLC (NASDAQ:LIVN) released its quarterly earnings data on Wednesday, November, 2nd. The company reported $0.58 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.01. The business earned $252.60 million during the quarter, compared to analysts' expectations of $246.53 million. LivaNova had a negative net margin of 9.14% and a positive trailing twelve-month return on equity of 9.28%.

What guidance has LivaNova issued on next quarter's earnings?

LivaNova updated its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided EPS guidance of $2.25-$2.45 for the period, compared to the consensus estimate of $2.30. The company issued revenue guidance of $1.08 billion-$1.10 billion, compared to the consensus revenue estimate of $1.01 billion.

What is Damien McDonald's approval rating as LivaNova's CEO?

47 employees have rated LivaNova Chief Executive Officer Damien McDonald on Glassdoor.com. Damien McDonald has an approval rating of 77% among the company's employees.

What other stocks do shareholders of LivaNova own?

Based on aggregate information from My MarketBeat watchlists, some companies that other LivaNova investors own include BioTelemetry (BEAT), Occidental Petroleum (OXY), Pfizer (PFE), Amarin (AMRN), Genocea Biosciences (GNCA), AbbVie (ABBV), Abbott Laboratories (ABT), ACADIA Pharmaceuticals (ACAD), Chipotle Mexican Grill (CMG) and CRISPR Therapeutics (CRSP).

What is LivaNova's stock symbol?

LivaNova trades on the NASDAQ under the ticker symbol "LIVN."

Who are LivaNova's major shareholders?

LivaNova's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (11.99%), Primecap Management Co. CA (8.55%), State Street Corp (4.78%), Barrow Hanley Mewhinney & Strauss LLC (4.56%), Eminence Capital LP (3.90%) and Dimensional Fund Advisors LP (1.93%). Insiders that own company stock include Alfred J Novak, Damien Mcdonald, Daniel Jeffrey Moore and Marco Dolci.
View institutional ownership trends.

How do I buy shares of LivaNova?

Shares of LIVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is LivaNova's stock price today?

One share of LIVN stock can currently be purchased for approximately $54.45.

How much money does LivaNova make?

LivaNova (NASDAQ:LIVN) has a market capitalization of $2.91 billion and generates $1.04 billion in revenue each year. The company earns $-135,820,000.00 in net income (profit) each year or ($1.75) on an earnings per share basis.

How many employees does LivaNova have?

The company employs 3,000 workers across the globe.

How can I contact LivaNova?

LivaNova's mailing address is 20 EASTBOURNE TERRACE, LONDON X0, W2 6LG. The official website for the company is www.livanova.com. The company can be reached via phone at 442033250660, via email at investor.relations@livanova.com, or via fax at 281-218-9332.

This page (NASDAQ:LIVN) was last updated on 12/7/2022 by MarketBeat.com Staff